Press release
Renal Cancer Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape
Discover the latest drugs and treatment options in the Renal Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Renal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Renal Cancer Pipeline Report
* In July 2025, Merck Sharp & Dohme LLC announced a study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).
* In July 2025, Bristol-Myers Squibb announced a study is to assess the safety and efficacy of nivolumab combined with ipilimumab in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC) or metastatic RCC (mRCC) in India.
* DelveInsight's Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
* The leading Renal Cancer Companies such as Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co., Inc, X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals, Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd and others.
* Promising Renal Cancer Pipeline Therapies such as Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461 , and others.
Stay ahead with the most recent pipeline outlook for Renal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Renal Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Renal Cancer Emerging Drugs Profile
* Atezolizumab : Genentech
Atezolizumab is a monoclonal antibody. It is designed to bind with a protein called PD-L1 expressed on tumor cells and tumor-infiltrating immune cells by blocking its interactions with both PD-1 and B7.1 the drug candidate are programmed cell death-1 ligand-1 inhibitors. Currently it is in Phase III stage of clinical trial evaluation to treat Renal Cancer.
* Olaparib: AstraZeneca
Olaparib is a potent and orally active poly (ADP-ribose) polymerase PARP inhibitor thereby blocking the repair of single-strand DNA breaks resulting in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination being developed for the treatment of renal cell carcinoma. Currently being evaluated in the Phase II studies.
* MK-4830 : Merck & Co., Inc
MK-4830 is an investigational first-in-class human monoclonal antibody that inhibits the binding of immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Renal Cancer.
* ALLO-316 : Allogene Therapeutics
ALLO-316, an AlloCAR T Trademark investigational product that targets CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors the drug candidate has received Fast Track Designation (FTD) from U.S FDA based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinoma. The drug is in Phase I stage of clinical trials.
The Renal Cancer Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cancer Treatment.
* Renal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Renal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cancer market
Explore groundbreaking therapies and clinical trials in the Renal Cancer Pipeline. Access DelveInsight's detailed report now! @ New Renal Cancer Drugs [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Renal Cancer Companies
Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co., Inc, X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals, Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd and others.
Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical
Renal Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Renal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Renal Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Renal Cancer Pipeline Report
* Coverage- Global
* Renal Cancer Companies- Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co., Inc, X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals, Inc, Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd and others.
* Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461 , and others.
* Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Renal Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Renal Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Renal Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* Atezolizumab: Genentech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Olaparib: AstraZeneca
* Early Stage Products (Phase I)
* Allogene Therapeutics: ALLO-316
* Inactive Products
* Renal Cancer Key Companies
* Renal Cancer Key Products
* Renal Cancer - Unmet Needs
* Renal Cancer - Market Drivers and Barriers
* Renal Cancer - Future Perspectives and Conclusion
* Renal Cancer Analyst Views
* Renal Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=renal-cancer-pipeline-outlook-report-2025-key-75-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Cancer Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4123604 • Views: …
More Releases from ABNewswire
Willow Creek Coffee Company Pioneers Roast-to-Order Model Bringing Cafe Quality …
Artisan coffee roaster Willow Creek Coffee Company launches nationwide delivery of freshly roasted beans sourced globally and roasted upon order. The sustainable business model builds community around exceptional coffee while revolutionizing freshness standards in specialty coffee.
Willow Creek Coffee Company emerges in the competitive specialty coffee landscape with a compelling proposition that prioritizes freshness, quality, and community building over conventional retail distribution models. The company's launch at willowcreekcoffeecompany.com introduces coffee lovers…
New analysis reveals why leading B2B companies dominate ChatGPT search results
After analyzing over 800,000 AI citations, marketing expert Sebastian Ocampo reveals why 89% of B2B buyers now use AI to research vendors and why most companies remain invisible. New data shows competitor blogs outperform traditional sources 56% of the time in ChatGPT results. Ocampo shares his five-step framework for capturing AI search visibility before your market gets locked out by early movers.
SWITZERLAND - Oct 31, 2025 - According to Sebastian…
Astral Signature Revolutionizes Sustainable Fashion with Mindfulness-Inspired De …
New lifestyle brand Astral Signature combines print-on-demand technology with astrology and self-growth themes to serve conscious consumers across North America. The company's expansion includes Amazon launch and exclusive 2026 World Cup collections targeting purpose-driven fashion seekers.
Astral Signature establishes itself as a pioneering force in conscious fashion following its 2025 launch that brings mindfulness-inspired apparel to intentional consumers throughout the United States, Mexico, and Canada. The brand's rapid expansion across astralsignature.com,…
Quest Auto Sales Transforms Used Cars for Sale Market with a Customer-First Fina …
Quest Auto Sales at 4501 L St, Omaha, offers flexible financing and transparent pricing on pre-owned vehicles, driving growth through customer referrals and personalized service in the local market.
The pre-owned vehicle market in Omaha is shifting as Quest Auto Sales [https://www.questautosales.com/] introduces a financing approach that prioritizes customer needs over rigid sales quotas. Located at 4501 L St in Omaha, NE 68117, the dealership has built its reputation on flexible…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
